glp-1 fatty liver disease Multiple target tissue effects of analogues on non-alcoholic (NAFLD) and non-alcoholic steatohepatitis (NASH) The Emerging GLP-1S & Fatty Liver -

Research suggests that taking 1800 mg of alpha-lipoic acid daily for 20 weeks reduces body weight in people who are overweight

For instance, the combination of GLP-1RA and enzyme inhibitors of proinflammatory, lipogenesis, pro-apoptotic, and pro-oxidative stress processes could be evaluated in metabolic diseases

Here we show that secretins, in addition to contributing to protein secretion and pilus-mediated host attachment, also contribute to motility and biofilm formation

Oral Treatment Without GI Issues (Future) Bioglutide Phase 2 reported lower GI adverse events compared to existing GLP-1 therapies, though this requires confirmation in larger trials